Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose: Toll-like receptors (TLRs) are involved in the recognition of nucleic acids (viral, bacterial, and possibly self) and have been implicated in several auto-immune diseases. In primary Sjögren’s syndrome (pSS) TLR7-induced B cell activation (e.g. by EBV) has been implicated in the immunopathology. An increased expression of TLR7 mRNA has been found in the parotid gland of pSS patients. In addition, TLR7 specifically recognizes ssRNA from viruses, and possibly self-ssRNA, with which Ro- and/or La-proteins form complexes, facilitating anti-SSA/SSB auto-antibody production, one of the hallmark disease parameters of pSS. Interestingly, EBV-transformed B cells have been shown to express the IL-7R and secrete IL-7. Recently, we found increased levels of IL-7 and its receptor in the minor salivary gland of pSS patients. Our purpose was to investigate the role of IL-7/IL-7 receptor-mediated immune activation in TLR7-induced B cell activation in pSS patients.
Methods: Isolated CD4 T cells and CD19 B cells from HC (n=7) and pSS patients (n=5) were co-cultured with and without a TLR7 agonist (TLR7A, Gardiquimod) in the presence or absence of CD14 monocytes/macrophages. Additionally, PBMCs (HC n=5, pSS n=8) were cultured with TLR7A with and without soluble human IL-7R (shuIL7R) and fully human anti-human IL-7 mAb. Proliferation of T cells and B cells was measured using 3H-thymidine incorporation and Ki67 expression (FACS analysis). Activation markers (CD19, HLA-DR, CD25) and intracellular IL-7 and IL-7Rα expression by B cells were measured by FACS analysis.
Results: A strongly TLR7A-increased proliferation of T and B cell co-cultures was associated with significant and selective increases in Ki67-proliferating CD19 B-cells (HC from 1.2% to 9.3%, p<0.01 vs. pSS from 1.2% to 7.0%, p<0.05), but not CD4 T-cells. Additionally, markers of activation on CD19 B cells (HC: CD25+ from 42.2% to 80.1%; CD19 MFI from 26.8% to 63.4%; HLA-DR MFI from 214 to 649) were significantly increased as well, equally effective in HC and pSS (all p<0.05). TLR7-induced B cell activation was increased in the presence of monocytes (Ki67+ B cells: HC from 0.9% to 30.2% vs. pSS from 1.0% to 11.6%, both p<0.05). IL-7R blockade markedly inhibited lymphocyte proliferation of TLR7A stimulated PBMCs from HC (from 8880 to 2289 cpm; p<0.05) and pSS patients (from 8580 to 4802 cpm; p<0.01), which was associated by a selective inhibition of Ki67-proliferating B cells (from 47.5% to 9.4%). The specific role of IL-7R-mediated activation was supported by an increase in intracellular IL-7Rα and IL-7 upon TLR7 triggering in B cells. The role of IL-7 was confirmed by blockade of TLR7-induced B cell activation with a fully human anti-IL-7 mAb (mean inhibition 50%, p<0.05).
Conclusion: TLR7A-induced B cell activation is potently and selectively inhibited by IL-7 and IL-7R blockade. Together with the up regulation of IL-7 and IL-7R in B cells upon TLR7 activation, these results suggest that shuIL-7R/anti-IL-7 mAb blocks an autocrine function of IL-7 in B cells. This indicates that IL-7/IL-7R blockade, targeting not only T cells as previously shown, but also B cells, represents an interesting new therapeutic approach in pSS.
Disclosure:
A. Bikker,
None;
C. R. Willis,
Amgen Inc. Seattle, WA, USA,
3;
A. A. Kruize,
None;
J. W. J. Bijlsma,
None;
F. P. J. G. Lafeber,
None;
J. A. G. van Roon,
None.
« Back to ACR/ARHP Annual Meeting 2012
ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-7-and-il-7-receptor-blockade-to-selectively-inhibit-tlr7-induced-b-cell-activation-in-primary-sjogrens-syndrome/